 NEW YORK, Dec. 01, 2020 GLOBE NEWSWIRE -- Ovid Therapeutics Inc. NASDAQ: OVID, a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced topline results from the Companys Phase 3 NEPTUNE clinical trial of OV101 gaboxadol for the treatment of Angelman syndrome. 